NCT05837884 Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
| NCT ID | NCT05837884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | Healthy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-09-05 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-09-05 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions. Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
Eligibility Criteria
Inclusion Criteria: * Must meet criteria of the high-risk population as described with one of the below criteria * ≥ 30 years AND * first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer. OR * Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer ' * Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care Exclusion Criteria: * • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy. * Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia * Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05837884 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05837884 currently recruiting?
Yes, NCT05837884 is actively recruiting participants. Contact the research team at iritavi@tlvmc.gov.il for enrollment information.
Where is the NCT05837884 trial being conducted?
This trial is being conducted at Beersheba, Israel, Haifa, Israel, Petah Tikva, Israel, Tel Aviv, Israel.
Who is sponsoring the NCT05837884 clinical trial?
NCT05837884 is sponsored by Tel-Aviv Sourasky Medical Center. The trial plans to enroll 2,000 participants.